Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Key Points

• Avalo Therapeutics experienced a 38.4% decrease in short interest in August, with total short shares falling to 55,600.
• The company's stock is currently trading at $10.20, down 4.4%, and has a 12-month high of $16.00 and a low of $3.39.
• Several analysts have issued a Buy rating for Avalo Therapeutics, with a consensus target price of $30.00.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a significant decrease in short interest in August. As of August 31st, there was short interest totaling 55,600 shares, a decrease of 38.4% from the August 15th total of 90,200 shares. Currently, 0.5% of the company's shares are short sold. Based on an average trading volume of 194,400 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 194,400 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.5% of the company's shares are short sold.

Avalo Therapeutics Trading Down 4.4%

Shares of NASDAQ AVTX traded down $0.47 during trading on Monday, reaching $10.20. The company had a trading volume of 161,525 shares, compared to its average volume of 120,148. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $16.00. The business's 50-day moving average is $8.15 and its 200 day moving average is $6.36.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.43) by ($0.49). As a group, equities analysts forecast that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on AVTX shares. Cowen started coverage on Avalo Therapeutics in a report on Friday, September 5th. They issued a "buy" rating for the company. Cantor Fitzgerald started coverage on Avalo Therapeutics in a report on Friday, August 15th. They issued an "overweight" rating for the company. TD Cowen started coverage on Avalo Therapeutics in a report on Friday, September 5th. They issued a "buy" rating for the company. Finally, HC Wainwright upgraded Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price objective for the company in a report on Monday, June 2nd. Nine investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $30.00.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently modified their holdings of the business. Northern Trust Corp purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at $168,000. Allostery Investments LP boosted its position in shares of Avalo Therapeutics by 46.1% during the first quarter. Allostery Investments LP now owns 107,141 shares of the company's stock valued at $858,000 after buying an additional 33,827 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in shares of Avalo Therapeutics by 19.3% during the first quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company's stock valued at $5,264,000 after buying an additional 106,389 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Avalo Therapeutics during the first quarter valued at $7,209,000. Finally, RWA Wealth Partners LLC purchased a new stake in shares of Avalo Therapeutics during the first quarter valued at $2,505,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.